"The Treg intervention aims to prevent the development and progression of type-1 diabetes, freeing people like me from the daily grind of insulin therapy and lifelong fear of complications," said Mary Rooney, 39, one of the patients who underwent the trial.
One of the patients in the trial, Mary Rooney, 39, said: The work of Dr Bluestone and his team offers new hope for people with type-1 diabetes. Targets for future investigative trials include diseases such as lupus, rheumatoid arthritis, obesity, certain cardiovascular disease and some neurologica
Date: Nov 27, 2015
Category: Health
Source: Google
Immunotherapy for type 1 diabetes deemed safe in first US trial
Trial participant Mary Rooney, 39, who was diagnosed with T1D four years ago, said she has experienced no side effects from Treg treatment. "The work of Dr. Bluestone and his team offers new hope for people with type 1 diabetes and other autoimmune disorders," Rooney said. "The Treg intervention aim